Document is current
Any future updates will be listed below
-
Authors
Royle, Kara-Louise https://orcid.org/0000-0003-0225-1199
Cairns, David A.
-
Funding
Funding for this research was provided by:
Cancer Research UK (C7852/A25447)
- License Information
-
More Information
Article History
Received: 12 July 2019
Accepted: 21 June 2021
First Online: 4 August 2021
Declarations
:
: Informed consent was required for participants to enter both Myeloma IX and Myeloma XI. Ethical approval was also sought and granted for each trial, from the North West Multi-centre Research Ethics Committee for Myeloma IX, and the Oxfordshire Research Ethics Committee A for Myeloma XI.
: Not applicable
: KLR reports grants and non-financial support from Celgene Corporation, grants and non-financial support from Merck Sharpe & Dohme, grants and non-financial support from Amgen and grants and non-financial support from Takeda Oncology, during the conduct of the study. DAC reports grants and non-financial support from Celgene Corporation, grants and non-financial support from Merck Sharpe & Dohme, grants and non-financial support from Amgen and grants and non-financial support from Takeda Oncology, during the conduct of the study.
